Aricept Articles

Bayer Files For Metrifonate Approval In EU, Then USA

13 November 1997

Mixed Results From Japanese Drugmakers

12 November 1997

Efficacy And Safety Of Aricept Questioned

29 October 1997

Tokyo Stock Comment

23 October 1997

Pfizer's Healthy Growth Lifted By Alliance Products

16 October 1997

Aricept In Germany

2 October 1997

Focus On Exelon For Alzheimer's Disease

14 August 1997

1st Approval For Novartis' Exelon; 2nd For Revasc

7 August 1997

Pfizer Enters New Product Cycle With Strong Potential

7 August 1997

Tokyo Stock Comment

24 July 1997

Stock Comment Tokyo

17 July 1997

Pfizer's Good Volume Growth Marred By Strong $

17 July 1997

Euro Clearance For Aricept

17 July 1997

Novartis Unveils Strong Product Pipeline

1 July 1997

W-L To Phase-Out Cognex Marketing

19 June 1997

Tokyo Stock Comment

12 May 1997

Forex Impacts Sales At Pfizer, Merck And S-P

22 April 1997

Eisai Launches Aricept In The UK, Its Second Market

8 April 1997

Enhanced R&D And Global Expansion At Eisai

7 April 1997

Eisai Expands In Europe

25 March 1997

NEW YORK STOCK COMMENT

17 March 1997

Aricept Approved In Second Market

3 March 1997

US 4th Qtr/Year-End Results See Strong Growth

27 January 1997

Eisai's Aricept Available In USA, Its First Market

27 January 1997

Zocor "Will Be World's Top-Selling Drug In 2005"

13 January 1997

Tokyo Stock Comment

16 December 1996

Stock Commentary: Tokyo

9 December 1996

First Approval Of Eisai's Aricept For Alzheimer's

2 December 1996

Sandoz' Alzheimer's Drug; International Data Revealed

2 December 1996

Zoloft Gets OCD Indication

4 November 1996

Galanthamine Enters Ph III In USA For Alzheimer's

28 October 1996

Pfizer Drops Tenidap For RA, But OA Still An Option

7 October 1996

Eisai Files For Aricept In USA; Phase III Data

8 April 1996

Accelerated Approval For Pfizer's Aricept?

1 April 1996

Japan stock market week to Nov 14